Details for Patent: 11,642,317
✉ Email this page to a colleague
Which drugs does patent 11,642,317 protect, and when does it expire?
Patent 11,642,317 protects EYSUVIS and INVELTYS and is included in two NDAs.
This patent has nineteen patent family members in seven countries.
Drugs Protected by US Patent 11,642,317
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alcon Labs Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | 11,642,317 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| Alcon Labs Inc | INVELTYS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210565-001 | Aug 22, 2018 | RX | Yes | Yes | 11,642,317 | ⤷ Subscribe | Y | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,642,317
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2013256130 | ⤷ Subscribe | |||
| Australia | 2018201772 | ⤷ Subscribe | |||
| Australia | 2020203213 | ⤷ Subscribe | |||
| Canada | 2871778 | ⤷ Subscribe | |||
| European Patent Office | 2844295 | ⤷ Subscribe | |||
| European Patent Office | 4008355 | ⤷ Subscribe | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
